{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:17:43Z","timestamp":1760645863111},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JRR"],"published-print":{"date-parts":[[2011]]},"DOI":"10.1269\/jrr.11036","type":"journal-article","created":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T13:22:54Z","timestamp":1314883374000},"page":"674-679","source":"Crossref","is-referenced-by-count":9,"title":["The Radiotherapy with Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Treatment Is an Effective Therapeutic Option in Patients with Advanced or Metastatic Bladder Cancer"],"prefix":"10.1093","volume":"52","author":[{"given":"Masaomi","family":"IKEDA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumasa","family":"MATSUMOTO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzuru","family":"NIIBE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takefumi","family":"SATOH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"FUJITA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"IWAMURA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"ISHIYAMA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"KOTANI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushige","family":"HAYAKAWA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"BABA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Sternberg CN, <i>et al<\/i> (1988) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol <b>139<\/b>: 461-469.","DOI":"10.1016\/S0022-5347(17)42494-3"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sternberg CN, <i>et al<\/i> (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer <b>64<\/b>: 2448-2458.","DOI":"10.1002\/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Loehrer PJ, <i>et al<\/i> (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol <b>10<\/b>: 1066-1073.","DOI":"10.1200\/JCO.1992.10.7.1066"},{"key":"4","unstructured":"4. Pollack A and Zagars GZ (1996) Radiotherapy for stage T3b transitional cell carcinoma of the bladder. Semin Urol Oncol <b>14<\/b>: 86-95."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. De Neve W, <i>et al<\/i> (1995) Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. Radiother Oncol <b>36<\/b>: 183-188.","DOI":"10.1016\/0167-8140(95)01586-6"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mothersill C, <i>et al<\/i> (1990) The effect of radiation and cytotoxic platinum compounds on the growth of normal and tumour bladder explant cultures. Acta Oncol <b>29<\/b>: 179-184.","DOI":"10.3109\/02841869009126542"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kaufman DS, <i>et al<\/i> (2009) Phase I&ndash;II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology <b>73<\/b>: 833-837.","DOI":"10.1016\/j.urology.2008.09.036"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hagan MP, <i>et al<\/i> (2003) RTOG 97-06: initial report of a phase I&ndash;II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys <b>57<\/b>: 665-672.","DOI":"10.1016\/S0360-3016(03)00718-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Rodel C, <i>et al<\/i> (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol <b>20<\/b>: 3061-3071.","DOI":"10.1200\/JCO.2002.11.027"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kaufman DS, <i>et al<\/i> (2000) The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I\/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist <b>5<\/b>: 471-476.","DOI":"10.1634\/theoncologist.5-6-471"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Chauvet B, <i>et al<\/i> (1996) Concurrent cisplatin and radiotherapy for patients with muscle-invasive bladder cancer who are not candidates for radical cystectomy. J Urol <b>156<\/b>: 1258-1262.","DOI":"10.1016\/S0022-5347(01)65563-0"},{"issue":"11","key":"12","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.1996.14.11.2901","volume":"14","year":"1996","ISSN":"http:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"},{"issue":"5","key":"13","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/0360-3016(93)90306-G","volume":"25","year":"1993","ISSN":"http:\/\/id.crossref.org\/issn\/0360-3016","issn-type":"print"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.258.7.931"},{"issue":"11","key":"15","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.1998.16.11.3576","volume":"16","author":"SHIPLEY W U","year":"1998","ISSN":"http:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1159\/000030361"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Lin CC, <i>et al<\/i> (2009) Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys <b>75<\/b>: 442-448.","DOI":"10.1016\/j.ijrobp.2008.11.030"},{"key":"18","unstructured":"18. Goldie JH and Coldman AJ (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep <b>63<\/b>: 1727-1733."},{"key":"19","unstructured":"19. Kennedy KA (1987) Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Des <b>2<\/b>: 181-194."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Basavaraju SR and Easterly CE (2002) Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. Med Phys <b>29<\/b>: 2391-2403.","DOI":"10.1118\/1.1509442"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0744"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. von der Maase H, <i>et al<\/i> (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol <b>23<\/b>: 4602-4608.","DOI":"10.1200\/JCO.2005.07.757"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. von der Maase H, <i>et al<\/i> (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol <b>18<\/b>: 3068-3077.","DOI":"10.1200\/JCO.2000.18.17.3068"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(00)00444-2"}],"container-title":["Journal of Radiation Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jrr\/article-pdf\/52\/5\/674\/2831256\/jrr-52-674.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T19:58:56Z","timestamp":1560542336000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jrr\/article-lookup\/doi\/10.1269\/jrr.11036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1269\/jrr.11036","relation":{},"ISSN":["0449-3060","1349-9157"],"issn-type":[{"value":"0449-3060","type":"print"},{"value":"1349-9157","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}